CTI BIOPHARMA CORP (CTIC) Stock Price & Overview
NASDAQ:CTIC • US12648L6011
Current stock price
The current stock price of CTIC is 9.09 USD. Today CTIC is down by 0%. In the past month the price increased by 1%. In the past year, price increased by 56.19%.
CTIC Key Statistics
- Market Cap
- 1.199B
- P/E
- N/A
- Fwd P/E
- 22.47
- EPS (TTM)
- -0.58
- Dividend Yield
- N/A
CTIC Stock Performance
CTIC Stock Chart
CTIC Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CTIC. When comparing the yearly performance of all stocks, CTIC is one of the better performing stocks in the market, outperforming 97.78% of all stocks.
CTIC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTIC. CTIC may be in some trouble as it scores bad on both profitability and health.
CTIC Earnings
CTIC Forecast & Estimates
14 analysts have analysed CTIC and the average price target is 10.7 USD. This implies a price increase of 17.66% is expected in the next year compared to the current price of 9.09.
For the next year, analysts expect an EPS growth of 66.63% and a revenue growth 121.03% for CTIC
CTIC Groups
Sector & Classification
CTIC Financial Highlights
Over the last trailing twelve months CTIC reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 52.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CTIC Ownership
CTIC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTIC
Company Profile
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 128 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Company Info
IPO: 1997-03-21
CTI BIOPHARMA CORP
3101 Western Ave Ste 800
Seattle WASHINGTON 98121 US
CEO: Adam R. Craig
Employees: 128
Phone: 12062827100.0
CTI BIOPHARMA CORP / CTIC FAQ
What does CTIC do?
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 128 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
What is the current price of CTIC stock?
The current stock price of CTIC is 9.09 USD.
Does CTI BIOPHARMA CORP pay dividends?
CTIC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTIC stock?
CTIC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for CTIC stock?
CTI BIOPHARMA CORP (CTIC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
Would investing in CTI BIOPHARMA CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTIC.